Spring Science is proud to join the RRPV Consortium! The Rapid Response Partnership Vehicle (RRPV) supports the Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure (MCM) product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats. The consortium establishes partnering networks, develops technology and plans, and solves key challenges in advance so that when critical issues arise a rapid response is possible.

Spring’s use of AI in microscopy image analysis offers a multitude of novel technological possibilities to the RRPV community, including multi-mechanism high-content screening; simultaneous stability, toxicity, formulation, and potency studies; and pre-clinical and clinical biomarker discovery and predictive modeling. We’re excited for the opportunity to unlock scientists’ superpowers in such a critical and meaningful way and look forward to working together!